1. Home
  2. AGIO vs ALEX Comparison

AGIO vs ALEX Comparison

Compare AGIO & ALEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGIO
  • ALEX
  • Stock Information
  • Founded
  • AGIO 2007
  • ALEX 1870
  • Country
  • AGIO United States
  • ALEX United States
  • Employees
  • AGIO N/A
  • ALEX N/A
  • Industry
  • AGIO Biotechnology: Pharmaceutical Preparations
  • ALEX Real Estate Investment Trusts
  • Sector
  • AGIO Health Care
  • ALEX Real Estate
  • Exchange
  • AGIO Nasdaq
  • ALEX Nasdaq
  • Market Cap
  • AGIO 1.4B
  • ALEX 1.3B
  • IPO Year
  • AGIO 2013
  • ALEX N/A
  • Fundamental
  • Price
  • AGIO $38.80
  • ALEX $19.05
  • Analyst Decision
  • AGIO Buy
  • ALEX Buy
  • Analyst Count
  • AGIO 6
  • ALEX 2
  • Target Price
  • AGIO $57.40
  • ALEX $24.00
  • AVG Volume (30 Days)
  • AGIO 976.6K
  • ALEX 354.7K
  • Earning Date
  • AGIO 07-31-2025
  • ALEX 07-24-2025
  • Dividend Yield
  • AGIO N/A
  • ALEX 4.73%
  • EPS Growth
  • AGIO N/A
  • ALEX 94.65
  • EPS
  • AGIO 11.13
  • ALEX 1.07
  • Revenue
  • AGIO $40,875,000.00
  • ALEX $238,308,000.00
  • Revenue This Year
  • AGIO $18.94
  • ALEX N/A
  • Revenue Next Year
  • AGIO $201.70
  • ALEX $1.76
  • P/E Ratio
  • AGIO $3.49
  • ALEX $17.63
  • Revenue Growth
  • AGIO 30.57
  • ALEX 8.21
  • 52 Week Low
  • AGIO $23.42
  • ALEX $15.70
  • 52 Week High
  • AGIO $62.58
  • ALEX $20.11
  • Technical
  • Relative Strength Index (RSI)
  • AGIO 58.69
  • ALEX 65.36
  • Support Level
  • AGIO $34.71
  • ALEX $18.48
  • Resistance Level
  • AGIO $37.73
  • ALEX $18.82
  • Average True Range (ATR)
  • AGIO 1.50
  • ALEX 0.25
  • MACD
  • AGIO 0.15
  • ALEX 0.05
  • Stochastic Oscillator
  • AGIO 82.21
  • ALEX 93.46

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About ALEX Alexander & Baldwin Inc. REIT Holding Company

Alexander & Baldwin Inc is a Hawaii commercial real estate company. The group owns, operates, and manages million square feet of retail, industrial, and office space in Hawaii. It is a real estate investment trust (REIT) and the owner of grocery and drug-anchored retail centers in the state. It functions through two segments namely Commercial Real Estate and Land Operations. The Commercial Real Estate segment owns and manages retail, industrial spaces, and also urban ground leases in Hawaii, thereby accounting for a majority of the company's revenue. The Land Operations segment actively manages the company's land and real estate-related assets and makes optimum utilization of these assets. Geographically, the activities are carried out across the United States.

Share on Social Networks: